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A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits
Th1 and Th17 Responses and Inflammasome
Activation in a Model of IL-23-Induced Psoriasis
Weiwen Jiang1,2, Fu-Gang Zhu1,2, Lakshmi Bhagat1, Dong Yu1, Jimmy X. Tang1, Ekambar R. Kandimalla1,
Nicola La Monica1 and Sudhir Agrawal1
Psoriasis is a chronic inflammatory skin disease that involves the induction of T-helper 1 (Th1) and T-helper 17
(Th17) cell responses and the aberrant expression of proinflammatory cytokines, including IL-1b. Copious
evidence suggests that abnormal activation of Toll-like receptors (TLRs) contributes to the initiation and
maintenance of psoriasis. We have evaluated an antagonist of TLR7, 8, and 9 as a therapeutic agent in an IL-23-
induced psoriasis model in mice. Psoriasis-like skin lesions were induced in C57BL/6 mice by intradermal
injection of IL-23 in the ear or dorsum. IL-23-induced increase in ear thickness was inhibited in a dose-dependent
manner by treatment with antagonist. Histological examination of ear and dorsal skin tissues demonstrated a
reduction in epidermal hyperplasia in mice treated with the antagonist. Treatment with antagonist also reduced
the induction of Th1 and Th17 cytokines in skin and/or serum, as well as dermal expression of inflammasome
components, NLRP3 and AIM2, and antimicrobial peptides. These results indicate that targeting TLR7, 8, and 9
may provide a way to neutralize multiple inflammatory pathways that are involved in the development of
psoriasis. The antagonist has the potential for the treatment of psoriasis and other autoimmune diseases.
Journal of Investigative Dermatology (2013) 133, 1777–1784; doi:10.1038/jid.2013.57; published online 14 March 2013
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease characterized
by hyperplasia of the epidermis, infiltration of leukocytes in
dermis and epidermis, and dilation and growth of blood vessels
(Nickoloff and Nestle, 2004). It affects approximately 1–2% of
the Caucasian population (Christophers, 2001). Almost 90% of
individuals with psoriasis are affected by the most common
form of the disease known as psoriasis vulgaris or plaque
psoriasis (Nestle et al., 2009). Many patients with psoriasis
have other medical issues. The frequency of seronegative
arthritis in individuals with psoriasis is approximately 6–42%.
Comorbidities observed in patients with psoriasis include type
2 diabetes, metabolic syndrome, obesity, poor quality of life,
and depression (Christophers, 2001; Gelfand et al., 2006; Azfar
and Gelfand, 2008; Davidovici et al., 2010; Mehta et al., 2010;
Nijsten and Stern, 2012).
Psoriatic skin lesions are infiltrated with immune cells,
predominantly CD3þ T cells and CD11cþ dendritic cells
(DCs; Chamian et al., 2005; Lowes et al., 2005). Infiltrating
T-helper 1 (Th1) and T-helper 17 (Th17) cells and activated
DCs produce proinflammatory cytokines, such as tumor
necrosis factor-a, IFN-g, IL-17, IL-22, IL-23, IL-12, and IL-1b.
These cytokines contribute to the pathogenesis of psoriasis by
activating keratinocytes and other resident cutaneous cells,
and by inducing abnormal expression of antimicrobial
peptides and other defensin genes (Zaba et al., 2009).
Treatment options for psoriasis range from topical agents for
mild disease and phototherapy for moderate disease to
systemic administration of drugs such as methotrexate, cyclos-
porine, or retinoids for severe disease. Several monoclonal
antibodies and a decoy receptor that target tumor necrosis
factor-a are used for the treatment of psoriasis, as are
monoclonal antibodies used for targeting the p40 subunit of
IL-12 and IL-23. Although these agents effectively alleviate the
symptoms, they do not cure the disease and are often
associated with underlying toxicities (Laws and Young,
2012). Agents with better therapeutic efficacy are still needed.
Toll-like receptors (TLRs) contribute to the pathogenesis of
psoriasis (Hari et al., 2010). TLRs are transmembrane receptors
that recognize pathogen-associated molecular patterns and
regulate innate immune defense against pathogens. TLR3, 7,
8, and 9 are located in the endosome. TLR3, TLR7, and TLR8
bind RNA, whereas TLR9 binds DNA containing
unmethylated CG dinucleotides (Kawai and Akira, 2010).
The expression and activity of TLR7, 8, and 9 are regulated
by cross talk between these receptors. Deletion of TLR7
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attenuates the pathology in mouse models of lupus, whereas
deletion of either TLR9 or TLR8 enhances the pathology in
these models (Christensen et al., 2006; Demaria et al., 2010;
Nickerson et al., 2010).
TLR7 and 9 are expressed on plasmacytoid DCs (pDCs) and
B cells, whereas TLR8 is expressed on myeloid DCs. Immune
complexes formed by self-nucleic acids and LL-37, an anti-
microbial peptide overexpressed in psoriatic lesions, activate
both pDCs and myeloid DCs (Lande et al., 2007; Ganguly
et al., 2009). The interaction between immune complexes and
TLRs induces the production of type I IFN, supports
autoreactive T-cell activation, and leads to psoriatic skin
lesions, in a self-sustaining feedback loop (Farkas and
Keme´ny, 2012). Imiquimod, a TLR7/8 agonist, exacerbates
psoriasis in patients and causes psoriatic lesions in mice.
Induction of psoriatic disease in rodents by this TLR agonist is
also dependent on the IL-23/Th17 pathway (van der Fits et al.,
2009; Patel et al., 2011). Inhibition of TLR-mediated immune
responses may provide another approach to the treatment of
psoriasis.
Synthetic oligonucleotides that act as antagonists of TLR7
and/or TLR9 exert therapeutic effects in preclinical models of
autoimmune diseases such as lupus, experimental autoim-
mune encephalitis, arthritis, and uveitis (Zeuner et al., 2002;
Ho et al., 2003; Dong et al., 2004; Barrat et al., 2007;
Fujimoto et al., 2009; Lenert 2010). We have reported the
development of a class of synthetic oligonucleotide-based
compounds that inhibits TLR7 and TLR9 activation. We
designed these compounds based on structure–activity rela-
tionship studies of immune-stimulatory oligonucleotides, in
which nucleotide and backbone modifications affected their
activity (Wang et al., 2009; Yu et al., 2009). Now we have
created a class of oligonucleotide-based antagonist
compounds that inhibit the induction of cytokine production
mediated by TLR7, 8, and 9 in human cell-based assays and in
cynomolgus monkeys (Kandimalla et al., 2013).
We have investigated the effect of an antagonist of TLR7, 8,
and 9 on the induction of the Th1 and Th17 pathways and
inflammasome activation in a mouse model of psoriasis.
Treatment with the antagonist regulated inflammatory gene
expression and reduced skin lesions. These studies demon-
strate the therapeutic potential of the TLR7, 8, and 9 antagonist
for the treatment of psoriasis and other inflammatory skin
diseases.
RESULTS
Antagonist specifically inhibits TLR7-, 8-, and 9-mediated
immune responses
The antagonist specifically inhibits TLR7-, 8-, and 9-, but not
TLR3- and 4-, mediated NF-kB activation in HEK293 cells
expressing TLRs (Supplementary Figure S1 online). In mice,
where TLR8 is not functional (Sarvestani et al., 2012),
antagonist inhibited TLR7- and 9-mediated immune
responses (Supplementary Figure S2 online).
Antagonist reduces skin lesions in IL-23-induced psoriasis
IL-23 is a key cytokine that contributes to the propagation of
the Th17 response and induces psoriasis-like skin lesions in
mice (Chan et al., 2006; Zheng et al., 2007); thus, we used an
IL-23-induced psoriasis mouse model to evaluate the effect of
the TLR antagonist on psoriasis.
Skin lesions were induced in mice by intradermal injec-
tion of IL-23 into the left ear. Groups of IL-23-injected mice
were treated with increasing doses of antagonist adminis-
tered subcutaneously at the base of the ear. Measurement of
gross ear thickness showed that psoriatic mice had thicker
ears than did naive mice. Antagonist-treated mice had less
thickening than did those that received control oligo, and,
importantly, the antagonist reduced ear thickness in a dose-
dependent manner (Figure 1a). Hematoxylin and eosin
staining of ear sections showed that psoriatic mice had
epidermal hyperplasia and increased lymphocyte infiltration
within the dermis when compared with naive mice. Treat-
ment with antagonist decreased epidermal hyperplasia in a
dose-dependent manner (Figure 1b and c). Further, hema-
toxylin and eosin staining appeared to show that lymphocyte
infiltrate decreased with the administration of the antagonist,
although this was not quantified (Figure 1c). Control oligo-
nucleotide had no effect on ear thickness or skin histology
changes.
Treatment with antagonist inhibits Th17 and Th1 responses
IL-23 stimulates Th17 cells to produce IL-17, IL-21, and IL-22
(Di Cesare et al., 2009). Development of psoriatic-like lesions
in the IL-23 mouse model requires induction of Th17
cytokines, mainly IL-17A and IL-22 (Zheng et al., 2007;
Rizzo et al., 2011). To assess the effect of antagonist on the
induction of Th1 and Th17 responses, mice were injected
intradermally with IL-23 in the back, as it allows collection of
greater quantity of tissue samples than the ear. The duration of
the study was shortened to 6 days, as all histological changes
were clearly detectable by this time (data not shown).
IL-23-injected mice were treated with phosphate-buffered
saline or 15 mg kg 1 of antagonist subcutaneously at a
distal site. Tissue staining confirmed that IL-23 injection
resulted in epidermal hyperplasia and infiltration of inflam-
matory cells, whereas antagonist inhibited these alterations.
A control oligo was tested in a similar protocol at 15 mg kg 1
that showed minimal impact on epidermal hyperplasia
(Figure 2).
IL-23 injection induced a Th1 response as demonstrated by
the increase in serum levels of IL-6 and IL-12. The treatment
with antagonist resulted in a decrease in serum levels of IL-6
and IL-12, respectively (Supplementary Figure S3a online). In
agreement with serum cytokine levels, skin homogenates also
showed an increase in IL-6 levels in psoriatic mice and a 53%
reduction in IL-6 levels in animals treated with antagonist
(Supplementary Figure S3b online).
The expression of IL-17A, IL-17F, and IL-21 mRNA was
higher in skin biopsies of psoriatic mice than in skin biopsies
from naive mice. Interestingly, IL-23p19 mRNA was upregu-
lated, suggesting that a feedback mechanism controls its
expression. Importantly, treatment with antagonist inhibited
the expression of IL-21 by 67%, IL-23p19 by 31%, IL-17A by
40%, and IL-17F by 48% (Figure 3a). Protein levels of IL-17
were elevated at the IL-23 injection site and were reduced by
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30% upon treatment with the antagonist (Figure 3b). In
addition, IL-23 injection induced an increase in IFN-g expres-
sion in the skin (Supplementary Figure S4 online). Treatment
with antagonist reduced IFN-g expression with minimal
impact on IL-4 or IL-10 expression.
We observed the upregulation of mRNA for defensin B4, LL-
37, S100A4, and S100A7a in the skin of psoriatic mice.
Expression of these antimicrobial peptides has been observed
in skin lesions of psoriatic patients (Madsen et al., 1991;
Nestle et al., 2009; Zibert et al., 2010; Sua´rez-Farin˜as et al.,
2012). Treatment with the antagonist resulted in a decrease in
mRNA expression of defensin B4 (90%; Figure 4a), S100A4
(23%; Figure 4c), and S100A7a (76% Figure 4d); LL-37 mRNA
levels were also lower but the reduction did not reach
statistical significance (Figure 4b).
Antagonist inhibits the expression of IL-1b, NLRP3, and AIM2
IL-1b has a central role in cutaneous inflammation in psoriasis
(Nestle et al., 2009). Its expression is affected by the activation
of inflammasomes, including NLRP3 and AIM2 (Sims et al.,
2010). In psoriatic mice, IL-1b protein levels in skin were
higher than in naive controls. The mRNA levels for IL-1b,
NLRP3, and AIM2 were also higher. Treatment with the
antagonist resulted in a 77% decrease in IL-1b protein
(Figure 5a) and reduction of AIM2 (34%; Figure 5b), NLRP3
(57%; Figure 5c), and IL-1b mRNA (72%; Figure 5d) present in
injected tissue. A control oligo had minimal impact on IL-23-
induced gene expression, whereas antagonist reduced IL-23-
induced expression of IL-17A, IFN-g, NLRP3, and IL-1b
(Supplementary Figure S5).
Antagonist specifically inhibits TLR7- and TLR9-mediated
inflammasome activation in J774 cells
The activation of NLPR3 and of pro-IL-1b is regulated by NF-
kB transcription factor-activating stimuli, including TLR7 and
9 (Bauernfeind et al., 2012). We assessed the effects of the
antagonist on NLRP3 and IL-1b mRNA expression and IL-1b
secretion in vitro using mouse J774 cells. Cells were treated
with TLR9, TLR7, or lipopolysaccharide (TLR4 agonist) alone
or in combination with the antagonist. ATP was added to cells
as a stimulus for inflammasome assembly after treatment with
the agonist/antagonist combination. Treatment of J774 cells
with lipopolysaccharide or with agonist of TLR9 or TLR7
resulted in a significant induction of NLRP3 (Figure 6a) and IL-
1b (Figure 6b) mRNA expression. mRNA levels of both NLRP3
and IL-1b were significantly reduced when the antagonist was
added with the TLR9 or TLR7 agonist. The induction of NLRP3
and IL-1b mRNA by lipopolysaccharide was not affected by
the addition of the antagonist, in agreement with its specificity
for TLR7 and TLR9. Secretion of IL-1b in the cell supernatant
was dependent on the addition of ATP, in combination with
the TLR agonist. However, low levels of IL-1b protein were
detected in the supernatant of cells treated with agonist of
TLR9 or TLR7, in combination with the antagonist (Figure 6c).
DISCUSSION
We have evaluated an antagonist of TLR7, 8, and 9 in a mouse
model of psoriasis induced by IL-23. The results demonstrate
that the antagonist hinders the development of skin lesions,
reduces the Th1 and Th17 response, and inhibits inflamma-
some activation.
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Figure 1. Antagonist inhibits development of IL-23-induced psoriasis in mice. (a) Ear thickness of mice at day 16. Each bar represents the mean ear thickness
of seven mice. (b) Epidermal hyperplasia was quantified by measuring thickness in more than 10 fields, at intervals of 100mm in each section. (c) Ear
histopathological changes: (i) naive mice, (ii) IL-23-injected mice treated with phosphate-buffered saline (PBS), (iii) IL-23-injected mice treated with: 2.5, (iv) 5, and
(v) 15 mg kg 1 of antagonist, and (vi) 15 mg kg1 control oligo. Microscopy photographs display representative changes in the ears for each group. Black arrows
show epidermal hyperplasia; blue arrows indicate inflammatory cell infiltration. Bar ¼ 50mm. *Po0.05 versus PBS group. Error bar depicts SD.
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Injection of IL-23 into mice produces some of the clinical
features associated with psoriasis. Hyperproliferation of kera-
tinocytes and thickened epidermis with infiltration of mono-
nuclear cells were evident in the IL-23-injected tissues, similar
to the histological changes detected in psoriatic patients
(Figure 1; Chan et al., 2006; Zheng et al., 2007; Heidrick
et al., 2009). Increased mRNA levels for defensin B4,
S100A7a, S100A4, and LL-37 detected in the injected skin
were similar to those observed in psoriatic patients (Figure 4;
Madsen et al., 1991; Nestle et al., 2009; Zibert et al., 2010;
Sua´rez-Farin˜as et al., 2012). Treatment of mice with the
antagonist reduced skin lesions and expression of the
antimicrobial peptides, suggesting that blocking TLR7 and
TLR9 has therapeutic potential.
The observed therapeutic effect exerted by the antagonist is
associated with the inhibition of multiple cytokines that are
important for disease development. The inhibition of IL-6,
IFN-g, IL-12, IL-23, IL-21, and IL-17 demonstrate that the
antagonist inhibits both Th1 and Th17 responses (Figure 3,
Supplementary Figures S3 and S4 online). The inhibition of
T-cell responses hinges on the antagonist’s ability to suppress
TLR7 and TLR9 activation, and probably affects the induction
of IL-12 and IL-6 by cells such as pDCs that express both of
these receptors. These cells may contribute to disease devel-
opment in mice by interacting with immune complexes
carrying self-nucleic acids. Indeed, the antimicrobial peptide
LL-37 is overexpressed in the IL-23-injected mice and in
human psoriatic lesions (Figure 4), and has been shown to
bind to DNA and RNA and activate pDCs in vitro (Lande
et al., 2007; Ganguly et al., 2009). Keratinocytes show
increased TLR9 expression when exposed to LL-37 and have
increased production of type I IFN after subsequent treatment
with a TLR9 agonist (Morizane et al., 2012). In addition, IL-23
injection leads to an increase in TLR7 and 9 expression in
skin (data not shown). Furthermore, treatment with the
antagonist inhibits development of epidermal hyperplasia in
mouse dermis, following injection of LL-37 (data not shown).
These data suggest that the antagonist inhibits IL-6 and IL-12
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Figure 3. Decreased expression of IL-23 and T-helper 17 (Th17) cytokines in
skin samples of antagonist-treated mice. IL-23-injected mice were treated with
antagonist or phosphate-buffered saline (PBS). (a) Dorsal skin samples were
collected and the mRNA expression of IL-21, IL-23, IL-17A, and IL-17F was
analyzed by real-time quantitative PCR. (b) Dorsal skin samples taken at the
site of IL-23 injection were homogenized, centrifuged, and IL-17 content
in supernatants was measured by ELISA. *Po0.05 versus PBS group.
R.Q., relative quantity.
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Figure 2. Antagonist inhibits IL-23-induced dorsal skin epidermal
hyperplasia. C57BL/6 mice (n¼ 4) were injected with either phosphate-
buffered saline (PBS) or IL-23 intradermally in the dorsal skin, according to
the protocol shown in Supplementary Figure S3 online. PBS, 15 mg kg1
antagonist, or 15 mg kg1 control oligo was injected subcutaneously at a distal
site. (a) Dorsal skin histology changes: (i) naive mice received daily PBS
injection for 4 days (Naive), (ii) IL-23-injected treated with PBS (PBS), (iii)
IL-23-injected mice treated with 15 mg kg1 antagonist (Antagonist), and (iv)
IL-23-injected mice treated with 15 mg kg1 control oligo (Control).
(b) Epidermal hyperplasia was quantified by measuring thickness in more than
10 fields, at intervals of 100mm in each section. Bar ¼ 50mm. *Po0.05 versus
PBS group. Error bar depicts SD.
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expression by preventing the interaction between these
receptors and immune complexes.
Injection of IL-23 in mouse epidermis triggers gene expres-
sion signals that involve DCs and keratinocytes, and con-
tributes to the propagation of disease by inducing the
production of several proinflammatory cytokines (Di Cesare
et al, 2009). The upregulation of IL-23 mRNA is observed in
the IL-23-injected tissues and may be explained, in part, by a
feedback mechanism that involves DCs (Figure 3). This class
of antagonists suppresses TLR7- and TLR9-mediated cytokine
induction in human pDCs and in mice (Wang et al., 2009; Yu
et al., 2009; Kandimalla et al., 2013). It is possible that a
similar transcriptional regulatory effect is exerted in mice,
following the administration of the antagonist. The inhibition
of IL-12, IL-23, and IL-17 is an important aspect of psoriasis
therapy. Indeed, antibodies targeting the p19 subunit of IL-23,
IL-17, and IL-17R are currently in clinical development for the
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Figure 6. Antagonist specifically inhibits Toll-like receptor 9 (TLR9) and Toll-
like receptor 7 (TLR7) agonist-induced inflammasome activation in J774 cells.
J774 cells were primed with lipopolysaccharide (LPS; 100 ng ml1), TLR9
(1mg ml1), or TLR7 (50mg ml1) agonist in the presence or absence of
antagonist (10mg ml1) for 4 hours. Agonist-primed or resting (phosphate-
buffered saline; PBS) cells were then stimulated with ATP (5 mM) for 1 hour.
Cell lysates were processed for RNA isolation and quantitative real-time PCR
analysis for NLRP3 (a) and IL-1b (b) gene expression, whereas culture
supernatants were analyzed for IL-1b secretion (c). Data are representative of
three independent experiments. *Po0.05 versus agonist treated. R.Q., relative
quantity.
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antimicrobial peptides mRNA. IL-23-injected mice were treated with
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Figure 5. Antagonist inhibits inflammasome activation. (a) Dorsal skin
homogenates were analyzed for IL-1b levels by ELISA. Values of IL-1b
were normalized to total protein. The expression of AIM2 (b), NLRP3 (c),
and IL-1b mRNA (d) was analyzed by real-time quantitative PCR.
*Po0.05 versus phosphate-buffered saline (PBS) group. R.Q., relative
quantity.
W Jiang et al.
TLR Antagonist Suppresses Inflammation
www.jidonline.org 1781
treatment of patients with moderate-to-severe plaque psoriasis
(Johnson-Huang et al., 2012).
The inhibition of IL-1b, AIM2, and NLRP3 expression by
antagonist treatment suggests that the antagonist may extend
its inhibitory effects beyond the regulation of Th1 and Th17
pathways to inflammasome activation (Figure 5). Inflamma-
somes contribute to inflammatory response by regulating IL-1b
maturation and secretion (Schroder et al., 2010). IL-1b
influences Th17 maturation and cytokine production.
Dysregulation of inflammasome expression and IL-1b
secretion is associated with inflammatory diseases, including
psoriasis (Mills and Dunne, 2009). NLRP3 and AIM2
inflammasomes are expressed in keratinocytes and their
expression is upregulated in IL-23-injected mice and in
psoriatic lesions. In cultured keratinocytes, IFN-g induces
AIM2 expression (Dombrowski et al., 2011). The decreased
expression of AIM2 observed in the treated mice may be due
to the inhibition of inflammatory cytokine that ultimately
affects AIM2 expression.
Conversely, the expression of NLPR3 and of IL-1b precursor
is regulated by NF-kB transcription factor-activating stimuli.
NF-kB activation is in itself controlled, in part, by TLR
activation (Bauernfeind et al., 2012). The inhibitory effect
exerted by the antagonist on TLR7 and TLR9 activation may
affect the expression of the inflammasome components, as
well as that of IL-1b precursor. This conclusion is supported by
in vitro studies using mouse J774 cells in which transcription
of NLRP3 and IL-1b mRNA was induced by the exposure of
the cells to either a TLR7 or a TLR9 agonist and could be
controlled by the antagonist with a concomitant inhibition of
IL-1b secretion (Figure 6).
The data collected suggest that the antagonist may exert a
therapeutic effect by blocking the activation of TLR7 and 9.
The impact of TLR8 inhibition on this disease model is
unclear, because TLR8 has a limited role in the regulation of
innate immune responses in mice. Nonetheless, in view of the
cross talk described between these receptors, it is likely that an
antagonist capable of blocking these three receptors has
significant therapeutic potential in humans.
The antagonist of TLR7, 8, and 9 is a therapeutic agent that
has distinct characteristics from other therapeutic approaches.
The antagonist blocks TLR activation, thereby affecting the
signaling cascade that controls the expression of multiple
cytokines. This inhibition ultimately results in the simulta-
neous blockade of many cellular events. In addition, blockade
of TLR activation is not expected to perturb the triggering of
downstream signals mediated by other cellular events. Thus,
the mechanism of action of the antagonist is significantly
different from that of immunosuppressants or monoclonal
antibodies utilized for the treatment of psoriasis and other
autoimmune diseases. The former induce a global inhibitory
effect on the immune system, whereas the latter are limited to
the inhibition of a preselected target and are designed to
completely neutralize its activity. Thus, although the clinical
implications of the differences between the antagonist and
other therapeutic agents are not clear at this time, the unique
mechanism of action of this agent opens new opportunities for
the treatment of several diseases. We have initiated a Phase-2
randomized, placebo-controlled clinical trial in patients with
moderate-to-severe psoriasis to evaluate IMO-3100, an
antagonist of TLR7 and TLR9.
The therapeutic effects exerted by the antagonist reinforce
the notion that the activation of TLR7 and TLR9 is an
important component of the multifactorial process involved
in the development of psoriasis. The data suggest that by
targeting these receptors it is possible to neutralize multiple
inflammatory pathways that are intimately involved in the
pathology of inflammatory and autoimmune diseases. Thus,
the TLR7, 8, and 9 antagonist described herein may prove
advantageous over therapies that target individual cytokines
for the treatment of autoimmune diseases.
MATERIALS AND METHODS
Animals
Female C57BL/6 mice 6–8 weeks old were purchased from The
Jackson Laboratory (Bar Habor, ME). Mice were housed at the Idera
Pharmaceuticals, Cambridge, MA, animal facility. All protocols were
approved by the Idera Institutional Animal Care and Use Committee.
Induction of disease
Skin lesions were induced in groups of mice (n¼ 7) by intradermal
injection into the left ear with 0.5mg of mouse IL-23 (eBioscience, San
Diego, CA) in 20ml phosphate-buffered saline on day 0, 2, 4, 6, 10,
12, and 14. IL-23-injected mice were treated with subcutaneous
injection of 2.5, 5, or 15 mg kg 1 of antagonist on day 3, 6, 9, 12,
and 15. One group of IL-23-injected mice was treated with
15 mg kg 1 of a control oligonucleotide and another with phos-
phate-buffered saline, following the same dosing schedule as for the
antagonist. The IL-23-induced increase in ear thickness was mon-
itored using a Peacock dial thickness gauge, and ear samples were
collected on day 18.
The induction of lesions on dorsal skin was achieved by daily
intradermal injection of IL-23 (1mg) from day 0 to 3 (n¼ 7). IL-23-
treated mice were injected subcutaneously at a distal site with
15 mg kg 1 of antagonist, control oligo, or with phosphate-buffered
saline on days 3, 4, and 5. All mice were killed on day 6, and samples
were collected for evaluation (Supplementary Figure S6 online).
Synthesis and purification of TLR7, 8, and 9 antagonist
The antagonist oligonucleotide, 50-CTATCTGUC*G*TTCTCTGU-30
(C* is 5-methyl-dC, G* is 7-deaza-dG, underlined nucleotides are
20-O-methyl-ribonucleotides, and all others are 20-deoxynucleotides),
and the control oligonucleotide, 50-CTATCTCACCTTCTCTGT-30,
were synthesized and purified as described earlier (Wang et al.,
2009; Yu et al., 2009). The molecular weight of the antagonist and
control was 5,801 and 5,624, respectively, and contained
o0.075 EU mg 1 of endotoxin by the Limulus assay (Bio-
Whittaker, Walkersville, MD).
Measurement of cytokine content
Cytokine levels in serum and skin samples were measured by ELISA.
Skin cytokine level was calculated based on protein concentrations
measured with Bio-Rad Protein Assay (Bio-Rad Laboratories, Her-
cules, CA). All cytokines were measured by ELISA kits purchased from
R&D Systems (Minneapolis, MN), except IL-6 and IL-12, which were
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measured using paired antibodies purchased from BD Pharmingen
(San Jose, CA).
Quantitative real-time PCR analysis
Skin total RNA was isolated using RNeasy Mini kit (Qiagen, Valencia,
CA). RNA (1mg) was reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Invitrogen, Carlsbad, CA). Quanti-
tative real-time PCR was performed using StepOnePlus PCR system
(Invitrogen), and the relative amount of gene expression was calcu-
lated using hypoxanthine-guanine phosphoribosyltransferase as endo-
genous control. Relative quantity of mRNA was calculated as respect
to the mean of naive group, which is set to 1. Primer probe sets were
purchased from Invitrogen (details included in Supplementary
Material online).
Histology
Formalin-fixed ear samples were processed and stained with hema-
toxylin and eosin by Mass Histology Service (Worcester, MA).
Epithelial hyperplasia and leukocyte infiltration were assessed using
an Olympus I 81 light microscope. Epidermal hyperplasia was
quantified by measuring thickness in more than 10 fields, at intervals
of 100mm in each section.
Inflammasome activation in J774 cells
Murine cells J774A.1 (ATCC, Rockville, MD) were cultured in DMEM
supplemented with 10% heat-inactivated FBS (Thermo Fisher Scien-
tific, Waltham, MA) and antibiotics (penicillin G/streptomycin). Cells
were plated overnight in medium, primed with lipopolysaccharide
(100 ng ml 1), TLR9 (1mg ml 1), or TLR7 (50mg ml 1) agonist in the
presence or absence of antagonist (10mg ml 1) for 4 hours. Agonist-
primed or resting cells were stimulated with ATP (5 mM, Invivogen, San
Diego, CA) for 1 hour. Culture supernatants were analyzed for IL-1b
secretion by ELISA. Total RNA was isolated using the RNeasy Mini kit.
Statistical analysis
Student’s unpaired t-test was used to determine the statistical
significance between means of experimental group and control.
Po0.05 was considered statistically significant.
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